Autolus Therapeutics plc - Asset Resilience Ratio

Latest as of December 2025: 33.37%

Autolus Therapeutics plc (6A3A) has an Asset Resilience Ratio of 33.37% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Autolus Therapeutics plc to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€196.58 Million

≈ $229.82 Million USD Cash + Short-term Investments

Total Assets

€589.07 Million

≈ $688.68 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2023–2025)

This chart shows how Autolus Therapeutics plc's Asset Resilience Ratio has changed over time. See 6A3A equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Autolus Therapeutics plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Autolus Therapeutics plc (6A3A) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€196.58 Million	33.37%
Total Liquid Assets	€196.58 Million	33.37%

Asset Resilience Insights

Very High Liquidity: Autolus Therapeutics plc maintains exceptional liquid asset reserves at 33.37% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Autolus Therapeutics plc Industry Peers by Asset Resilience Ratio

Compare Autolus Therapeutics plc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Autolus Therapeutics plc (2023–2025)

The table below shows the annual Asset Resilience Ratio data for Autolus Therapeutics plc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	33.37%	€196.58 Million ≈ $229.82 Million	€589.07 Million ≈ $688.68 Million	-12.70pp
2024-12-31	46.08%	€360.64 Million ≈ $421.63 Million	€782.73 Million ≈ $915.09 Million	--
2023-12-31	0.00%	€0.00 ≈ $0.00	€375.38 Million ≈ $438.86 Million	--

pp = percentage points

About Autolus Therapeutics plc

F:6A3A Germany Biotechnology

Market Cap

$413.83 Million

€353.97 Million EUR

Market Cap Rank

#14030 Global

#1415 in Germany

Share Price

€1.33

Change (1 day)

+4.72%

52-Week Range

€1.06 - €2.24

All Time High

€40.10